Liver-Targeted Gene Therapy Shows Promise for Rare Metabolic Disorder
Researchers have successfully used siRNA technology in preclinical models to prevent neurological damage caused by glutaric aciduria type I. The approach targets the liver to stop the production of toxic metabolites that otherwise accumulate in the brain.
🔬ResearchPhoto: Medical Xpress
Key points
- GA1 is a rare metabolic disorder that causes toxic buildup in the brain.
- Researchers used siRNA to silence a liver gene, preventing the production of harmful metabolites.
- The treatment protected mouse models from neurological damage and improved survival.
A research team led by the Duke University School of Medicine has demonstrated a potential new treatment strategy for glutaric aciduria type I (GA1), a rare inherited metabolic condition. Currently, GA1 is managed through strict, lifelong dietary restrictions, yet many patients still face severe, irreversible neurological impairment due to the buildup of toxic byproducts that damage motor function areas in the brain.
The study, published in Science Translational Medicine, utilized small interfering RNA (siRNA) to silence a specific gene in the liver responsible for the faulty breakdown of the amino acid lysine. By shifting the focus to the liver, which the researchers identified as the primary source of the toxic metabolites, the team successfully protected mouse models from neurological injury. Treated neonatal mice showed significantly improved survival rates compared to untreated groups, even when maintained on high-protein diets.
What to know: While these results in animal models are encouraging, clinical trials in humans are the necessary next step to determine safety and efficacy. Because this research is in the preclinical stage, patients should continue following their current medical care plans and consult with their physicians before considering any changes to their treatment or dietary management.
The researchers noted that this siRNA-based approach could eventually offer a more convenient alternative to restrictive diets, potentially requiring only a few injections per year. Furthermore, the study identified specific blood plasma biomarkers that may assist doctors in monitoring therapeutic progress in future human applications.
Source Medical Xpress — medicalxpress.com/news/2026-11-silencing-liver-gene-brain-rare.html ↗
Read next
🏃FitnessExpert Advice on Hydration Gear Sparks Debate Among Recreational Runners
Olympic medalist Josh Kerr recently suggested that runners may not require hydration packs for distances under 12 miles, igniting a broader conversation about gear necess…
🏃FitnessA Structured Approach to Beginning a Strength and Cardio Routine
A new four-week training program offers beginners a guided path to incorporating strength training and cardiovascular exercise into their daily lives.
🧠Mind & Mental HealthThe Role of Daily Mobility Training in Managing Sedentary Tension
A two-week personal trial suggests that incorporating short, daily mobility exercises may help alleviate stiffness associated with sedentary desk work. Experts note that …
🧠Mind & Mental HealthNew Theoretical Framework Explores Memory Formation and Dementia
Researchers have proposed a new model suggesting the brain's limbic system functions similarly to generative AI, potentially offering a new way to understand and classify…
🏥Public HealthRecall Issued for Generic Propranolol Over Potential Metal Contamination
Breckenridge Pharmaceutical has initiated a voluntary recall of one lot of generic propranolol capsules due to the potential presence of metal fragments.
🥗NutritionUnderstanding Food Science: Why Some Leftovers Freeze Better Than Others
Freezing leftovers is an effective way to minimize food waste, though the success of the process depends on the cellular structure and composition of the food being store…